- •Diabetic Retinopathy
- •Preface
- •Contents
- •Contributors
- •Nonproliferative Diabetic Retinopathy
- •Nonproliferative Diabetic Retinopathy
- •Inflammatory Mechanisms
- •Microaneurysms
- •Vascular Permeability
- •Capillary Closure
- •Classification Of Nonproliferative Retinopathy
- •Macular Edema
- •Risk Factors For Progression Of Retinopathy
- •Severity of Retinopathy
- •Glycemic Control
- •The Diabetes Control and Complications Trial
- •Epidemiology of Diabetes Interventions and Complications Trial
- •The United Kingdom Prospective Diabetes Study
- •Hypertension
- •The United Kingdom Prospective Diabetes Study
- •Appropriate Blood Pressure Control in Diabetes Trials
- •Elevated Serum Lipid Levels
- •Pregnancy and Diabetic Retinopathy
- •Other Systemic Risk Factors
- •Management Of Nonproliferative Diabetic Retinopathy
- •Photocoagulation
- •Scatter Photocoagulation for Nonproliferative Diabetic Retinopathy
- •Scatter Photocoagulation for Proliferative Retinopathy
- •Focal Photocoagulation for Diabetic Macular Edema
- •Other Treatment of Diabetic Macular Edema
- •Medical Therapy
- •Aspirin And Antiplatelet Treatments
- •Aldose Reductase Inhibitors
- •Other Medical Treatments
- •Summary
- •Acknowledgment
- •References
- •Proliferative Diabetic Retinopathy
- •Development and Natural History
- •Histopathology and Early Development
- •Proliferation and Regression of New Vessels
- •Contraction of the Vitreous and Fibrovascular Proliferations
- •Retinal Distortion and Detachment
- •Burned-Out Proliferative Diabetic Retinopathy
- •Systemic Associations
- •Proliferative Diabetic Retinopathy and Glycemic Control
- •Other Risk Factors for Proliferative Diabetic Retinopathy
- •Rubeosis Iridis
- •Anterior Hyaloidal Fibrovascular Proliferation
- •Management of Proliferative Diabetic Retinopathy
- •Pituitary Ablation
- •Photocoagulation
- •Randomized Clinical Trials of Laser Photocoagulation
- •The Diabetic Retinopathy Study
- •Risks and Benefits Photocoagulation In The Drs
- •The Early Treatment Diabetic Retinopathy Study
- •Indications For Photocoagulation of Pdr
- •PRP and Macular Edema
- •PRP Treatment Techniques
- •Vitrectomy for PDR
- •Pharmacologic Treatment of PDR
- •Acknowledgment
- •References
- •Brief Historical Background
- •The Wesdr
- •Prevalence of Diabetic Retinopathy
- •Incidence of Diabetic Retinopathy
- •Diabetic Retinopathy in African American and Hispanic Whites
- •Native Americans and Asian Americans
- •Age and Puberty
- •Genetic and Familial Factors
- •Modifiable Risk Factors
- •Hyperglycemia
- •Clinical Trials of Intensive Treatment of Glycemia
- •Diabetes Control and Complications Trial
- •The United Kingdom Diabetes Prospective Study (UKPDS)
- •Hypertension
- •Lipids
- •Subclinical and Clinical Diabetic Nephropathy
- •Microalbuminuria and Diabetic Retinopathy
- •Gross Proteinuria and Retinopathy
- •Diabetic Retinopathy as a Risk Indicator of Subclinical Nephropathy
- •Other Risk Factors For Retinopathy
- •Smoking and Drinking
- •Body Mass Index and Physical Activity
- •Hormone and Reproductive Exposures in Women
- •Prevalence and Incidence of Visual Impairment
- •Conclusions
- •Acknowledgments
- •References
- •Introduction
- •Fluorescein Angiography
- •Properties
- •Side Effects
- •Normal Fluorescein Angiography
- •Terminology
- •Fluorescein Angiography in the Evaluation of Diabetic Retinopathy
- •Fluorescein Angiography in the Evaluation of Diabetic Macular Edema
- •Optical Coherence Tomography
- •Low-Coherence Interferometry
- •OCT Image Interpretation
- •OCT Technology Development
- •The Role of OCT in Diabetic Macular Edema
- •Morphologic Patterns of Diabetic Macular Edema
- •Clinical Applications of OCT in Diabetic Macular Edema
- •Conclusions
- •References
- •Diabetic primates
- •Type of Diabetes
- •Histopathology and Rate of Development of the Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic dogs
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic cats
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic rats
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neuronal disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic mice
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neural disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Other Rodents
- •Galactose Feeding
- •Nondiabetic Models in Which Growth Factors are Altered
- •VEGF overexpression
- •IGF overexpression
- •PDGF-B-deficient mice
- •Oxygen-Induced Retinopathy
- •Sympathectomy
- •Retinal Ischemia–Reperfusion
- •Summary
- •References
- •Introduction
- •Biochemistry and Genetics of The Polyol Pathway
- •Aldose Reductase
- •The Aldose Reductase Enzyme
- •The Aldose Reductase Gene
- •Polymorphisms of the AR Gene
- •Sorbitol Dehydrogenase
- •The Sorbitol Dehydrogenase Enzyme
- •The Sorbitol Dehydrogenase Gene
- •Ar Polymorphisms and Risk of Diabetic Retinopathy
- •Sdh Polymorphisms and Diabetic Retinopathy
- •Ar Overexpression
- •Sdh Overexpression
- •Ar “Knockout” Mice
- •Sdh-Deficient Mice
- •Osmotic Stress
- •Oxidative Stress
- •Activation of Protein Kinase C
- •Generation of AGE Precursors
- •Proinflammatory Events and Apoptosis
- •Ari Structures and Properties
- •Effects of Aris in Experimental Diabetic Retinopathy
- •The Polyol Pathway in Human Diabetic Retinopathy
- •The Sorbinil Trial
- •Perspective and Needs
- •Rationale for Defining the Pathogenic Role of the Polyol Pathway
- •Needs to be Met to Arrive at Anti-Polyol Pathway Therapy
- •References
- •Introduction to Diabetic Retinopathy
- •Biochemistry of Age Formation
- •Pathogenic Role of Ages In Diabetic Retinopathy
- •AGEs and Clinical Correlation of Diabetic Retinopathy
- •AGE Accumulation in the Eye
- •Effect of AGEs on Retinal Cells
- •RAGE in Diabetic Retinopathy
- •Other AGE Receptors in Diabetic Retinopathy
- •Anti-Age Strategies For Diabetic Retinopathy
- •Conclusion
- •References
- •Introduction
- •Dag-Pkc Pathway
- •Diabetes and Retinal Blood Flow
- •Basement Membrane and Ecm Changes
- •Vascular Permeability and Angiogenesis
- •Conclusions
- •References
- •Sources of Oxidative Stress in The Diabetic Retina
- •Overview
- •Mitochondrial Electron Transport Chain (ETC)
- •Advanced Glycation End (AGE) Product Formation
- •Cyclo-oxygenase (COX)
- •Flux Through Aldose Reductase (AR) Pathway
- •Activation of Protein Kinase C (PKC)
- •Endothelial NO Synthase (eNOS)
- •Inducible NOS (iNOS)
- •NADPH Oxidase
- •Antioxidants in Diabetic Retinopathy
- •Overview
- •Glutathione (GSH)
- •Superoxide Dismutase (SOD)
- •Catalase
- •Effects of Oxidative Stress in The Diabetic Retina
- •Overview
- •Growth Factors and Cytokines
- •Cytoxicity
- •Therapeutic Strategies For Reducing Oxidative Stress
- •Overview
- •Antioxidants
- •PKC Inhibitors
- •Inhibitors of the Renin-Angiotensin System
- •Inhibitors of the Polyol Pathway
- •HMG-CoA Reductase Inhibitors (Statins)
- •PEDF
- •Cannabinoids
- •Cyclo-oxygenase-2 (COX-2) Inhibitors
- •References
- •Pericyte Loss in the Diabetic Retina
- •Introduction
- •Origin and Differentiation
- •Morphology and Distribution
- •Identification
- •Function
- •Contractility
- •Role in Vessel Formation and Stabilization
- •Loss In Diabetic Retinopathy
- •Rats
- •Mice
- •Chinese Hamster
- •Animal Models Mimicking Retinal Pericyte Loss
- •Pdgf-B-Pdgf-Ssr
- •Angiopoietin-Tie
- •Vegf-Vegfr2
- •Mechanisms of Loss
- •Biochemical Pathways
- •Aldose Reductase
- •Age Formation
- •Modification of Ldl
- •Loss Through Active Elimination
- •Capillary Dropout in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Methods to Measure and Detect Capillary Dropout
- •Models to Study Retinal Capillary Dropout in Diabetes
- •Potential Mechanisms For Capillary Dropout
- •Capillary Cell Apoptosis
- •Proinflammatory Changes/Leukostasis
- •Microthrombosis/Platelet Aggregation
- •Consequences of Capillary Dropout
- •Macular Ischemia
- •Neovascularization
- •Macular Edema
- •Acknowledgments
- •References
- •Neuroglial Dysfunction in Diabetic Retinopathy
- •The Neurons of The Retina
- •The Glial Cells of The Retina
- •Diabetes Reduces Retinal Function
- •Diabetes Induces Neurodegeneration in The Retina
- •Neuroinflammation in Diabetic Retinopathy
- •Historical Perspective on Diabetic Retinopathy
- •Neuroglial Dysfunction in Diabetic Retinopathy.
- •References
- •Introduction
- •Inflammatory Cells Promote and Regulate The Development of Ischemic Ocular Neovascularization
- •VEGF as a Proinflammatory Factor in Diabetic Retinopathy
- •VEGF164/165 as a Proinflammatory Cytokine
- •Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- •Corticosteroids
- •Anti-VEGF Agents
- •Pegaptanib
- •Ranibizumab and Bevacizumab
- •Conclusions
- •Acknowledgment
- •References
- •Glia-Endothelial Interaction
- •Specialized Retinal Vessels Control Flux into Neural Tissue
- •Overview of Tight Junction Proteins
- •Claudins Confer Tight Junction Barrier Properties
- •Occludin Regulates Barrier Properties
- •Alterations in Occludin in Diabetic Retinopathy
- •Ve-Cadherin and Diabetic Retinopathy
- •Permeability in Diabetic Retinopathy
- •Summary and Conclusions
- •References
- •Introduction
- •Stages of Angiogenesis
- •Vascular Endothelial Growth Factor
- •Regulation of Vegf Expression in The Retina
- •Regulation of VEGF in Proliferative Diabetic Retinopathy
- •Regulation of VEGF in Nonproliferative Diabetic Retinopathy
- •Basic Vegf Biology
- •Receptors
- •Vegf’S Multiple Actions on Retinal Endothelial Cells
- •Main Signaling Pathways
- •Other Actions of Vegf
- •Proinflammatory Effects of VEGF
- •VEGF and Retinal Neuronal Development
- •VEGF and Neuroprotection
- •Modulation of Vegf Action By Other Growth Factors
- •Conclusion
- •References
- •Insulin-Like Growth Factor
- •Basic Fibroblast Growth Factor
- •Angiopoietin
- •Erythropoietin
- •Hepatocyte Growth Factor
- •Tumor Necrosis Factor
- •Extracellular Proteinases
- •The Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Proteinases in Retinal Neovascularization
- •Integrins
- •Endogenous Inhibitors of Neovascularization
- •Pigment Epithelium Derived Growth Factor
- •Angiostatin and Endostatin
- •Thrombospondin-1
- •Tissue Inhibitor of Matrix Metalloproteinases
- •Clinical Implications
- •Acknowledgments
- •References
- •Introduction
- •Pathogenesis
- •Vascular Endothelial Growth Factor (Vegf)
- •Vegf in Physiological and Pathological Angiogenesis
- •Vegf in Ocular Neovascularization
- •Vegf and Diabetic Retinopathy
- •Clinical Application of Anti-VEGF Drugs
- •Pegaptanib
- •Bevacizumab
- •Ranibizumab
- •Use of Anti-VEGF Therapies in Diabetic Retinopathy
- •Safety
- •Clinical Experience with Bevacizumab in Diabetic Retinopathy
- •Ranibizumab in Diabetic Macular Edema
- •Effect on Foveal Thickness and Macular Volume
- •Effect on Visual Acuity
- •Summary
- •References
- •Introduction
- •Pkc Inhibition With Ruboxistaurin
- •Early Clinical Trials With Rbx
- •Rbx and Progression of Diabetic Retinopathy
- •Ongoing Trials With Rbx
- •Rbx and Other, Nonocular Complications of Diabetes
- •Safety Profile of Rbx
- •Clinical Status of Rbx
- •Conclusions
- •References
- •The Role of Intravitreal Steroids in the Management of Diabetic Retinopathy
- •Clinical Efficacy
- •Safety
- •Pharmacology
- •Pharmacokinetics
- •Combination With Laser Treatment
- •Clinical Guidelines
- •Macular Edema Caused by Focal Parafoveal Leak
- •Widespread Heavy Diffuse Leak
- •Macular Edema and High-Risk Proliferative Retinopathy
- •Macular Edema Prior to Cataract Surgery
- •Juxtafoveal Hard Exudate With Heavy Leak
- •Control of Systemic Risk Factors
- •The Future of Intravitreal Steroid Therapy
- •References
- •Overview
- •Introduction and Historical Perspective
- •Growth Hormone and Diabetic Retinopathy
- •The IGF-1 System and Retinopathy
- •The Role of SST in Diabetic Retinopathy
- •Rationale for the Clinical use of Octreotide
- •Clinical evidence for sst as a therapeutic for pdr
- •Potential Reasons for Mixed Success in Clinical Trials
- •Future Direction: Sst Analogs in Combination Therapy
- •Conclusion
- •Acknowledgements
- •Introduction
- •Diabetic Retinopathy and Mortality
- •Diabetic Retinopathy and Cerebrovascular Disease
- •Diabetic Retinopathy and Heart Disease
- •Diabetic Retinopathy, Nephropathy, and Neuropathy
- •Conclusion
- •References
- •Name Index
2 Proliferative Diabetic Retinopathy
Ronald P. Danis and Matthew D. Davis
CONTENTS
DEVELOPMENT AND NATURAL HISTORY
SYSTEMIC ASSOCIATIONS
OTHER TYPES OF INTRAOCULAR NEOVASCULAR
PROLIFERATION IN DIABETES
MANAGEMENT OF PROLIFERATIVE DIABETIC RETINOPATHY
REFERENCES
ABSTRACT
Proliferative diabetic retinopathy continues to be a major cause of blindness throughout the world. The natural history demonstrates that its development is primarily related to progressive retinal ischemia from diabetic retinopathy. The primary complications leading to vision loss, tractional retinal detachment and vitreous hemorrhage, are dependent upon the relationship between the neovascular tissue and the vitreous. The major risk factors are duration of diabetes and the level of glycemic control of the patient, with glycemic control being the modifiable risk factor as demonstrated in the DCCT/EDIC and UKPDS trials. Timely treatment with laser photocoagulation has been demonstrated to be of immense value for the preservation of vision, as reported by the DRS, ETDRS, and other studies. Pars plana vitrectomy is indicated for some patients with vitreous hemorrhage, retinal detachment, and other complications. With growing understanding of the cell biology of diabetes complications, pharmacologic therapies are emerging as promising treatment options.
Key Words: Diabetes mellitus; Diabetic retinopathy; Neovascularization; Laser photocoagulation Vitrectomy.
DEVELOPMENT AND NATURAL HISTORY
Histopathology and Early Development
Endothelial proliferation and new vessel formation in the retina are stimulated by ischemia of its inner layers secondary to regional closure of the retinal capillary bed
From: Contemporary Diabetes: Diabetic Retinopathy
Edited by: E. Duh © Humana Press, Totowa, NJ
29
30 |
Danis and Davis |
(1–4). Retinal hypoxia induces upregulation of genes such as hypoxia inducible factor that in turn stimulate the production of a variety of endothelial mitogens, most notably vascular endothelial growth factor (VEGF). Chronic ischemia also produces a localized low-grade inflammatory response within the vessels, with the subsequent migration and stimulation of immunogenic cells in the tissue, which also produce a variety of mitogenic cytokines. These growth factors promote a neovascular (NV) response locally and by diffusing through the vitreous to other areas of the retina, to the optic disc, and into the anterior chamber (5–7).
The background of intraretinal lesions against which preretinal new vessels arise is variable. The risk of proliferative diabetic retinopathy (PDR) is greatest in eyes with severe NPDR (nonproliferative diabetic retinopathy, also called preproliferative retinopathy), characterized by the presence of soft exudates (cotton-wool patches), intraretinal microvascular abnormalities (IRMAs, a term chosen so as to be neutral about whether these abnormal vessels represent intraretinal new vessels or dilated preexisting vessels), venous beading, and extensive retinal hemorrhage or microaneurysms (Fig. 1). In the Diabetic Retinopathy Study (DRS) severe NPDR was basically defined as the presence of at least three of the four above-mentioned characteristics, each generally involving at least two quadrants of the fundus. About 50% of such eyes assigned to the untreated control group had developed PDR within 15 months (8). The presence and extent of retinal and optic nerve head NV in the diabetic retina are roughly correlated with the extent of capillary loss on fluorescein angiography (1).
Although there is little doubt that the presence of severe NPDR is predictive of subsequent NV, the characteristic intraretinal lesions are not always present when preretinal
Fig. 1. Severe nonproliferative diabetic retinopathy. Two prominent cotton-wool spots (soft exudates) are noted on the left side with a large blot hemorrhage between them. Venous beading is present where the superior branch of the superotemporal vein passes by the upper exudate. On the right are two faint soft exudates (arrows) and many intraretinal microvascular abnormalities. (Courtesy Early Treatment Diabetic Retinopathy Study Research Group.)
Proliferative Diabetic Retinopathy |
31 |
new vessels are first recognized. A possible explanation for this is the relatively transient nature of some of these lesions. Soft exudates usually disappear within 6–12 months. Blot hemorrhages and IRMA tend to disappear after extensive capillary closure, when the number of small vascular branches decreases and some small arterioles become white threads, producing a picture aptly described as featureless retina (Fig. 2).
Some, but probably a minority, of the IRMAs eventually develop into neovascular tissue (9). IRMAs feature endothelial proliferation and vascular caliber larger than retinal capillaries with loose adventitia, similar to NV lesions. A critical distinction is that IRMAs lie exclusively below the level of the internal limiting membrane (ILM) of the retina, whereas NV lies above the ILM, growing along the interface between the retina and posterior vitreous face, where they can become elevated as vitreous detachment occurs.
Although new vessels may arise anywhere in the retina, they are most frequently seen within 10–15 mm of the optic disc, and on the disc itself (Davis (10): 69% of 155 eyes with PDR; Taylor and Dobree (11): 73% of 86 eyes). In the DRS, among 1,377 control group eyes with new vessels present in baseline photographs, 15% had new vessels only on or within 1 disc diameter (DD) of the disc, 40% had new vessels only outside this zone, and 45% had new vessels in both zones (12).
Neovascularization of the optic disc (NVD) begins as fine loops or networks of vessels lying on the surface of the disc or bridging across the physiologic cup. The most satisfactory examining methods are those that provide a magnified stereoscopic view, either biomicroscopy with contact or precorneal lens or stereoscopic 30-deg photography. If any doubt remains, it can usually be resolved by fluorescein angiography, which demonstrates the profuse leakiness characteristic of preretinal new vessels. Wide-angle angiography can be helpful in identifying ischemia and NV, particularly when NV
Fig. 2. Early proliferative diabetic retinopathy. New vessels form a small wheel-like network (arrow) in the superotemporal quadrant of an eye with venous beading, cotton-wool spots (soft exudates), intraretinal microvascular abnormalities, and blot hemorrhages. (Courtesy Early Treatment Diabetic Retinopathy Study Research Group.)
32 |
Danis and Davis |
lesions are suspected (e.g., due to recent vitreous hemorrhage) but are not found on clinical examination. The possibility that the vitreous hemorrhage may come from a peripheral retinal tear, unrelated to diabetic retinopathy, should be kept in mind, and a careful examination of the peripheral fundus with scleral depression should be performed.
Early new vessels elsewhere (NVE) may be difficult to distinguish from IRMA, particularly if the IRMA are extensive and NVE do not yet show any of their unique features, such as formation of wheel-like networks, extension across both arterial and venous branches of the underlying retinal vascular network, accompanying fibrous proliferations, or elevation. The true nature of such borderline lesions soon becomes clear with careful follow-up.
NV requires a scaffold or matrix in which to grow (13); therefore, NV does not typically occur in areas where the vitreous has detached or has been surgically removed (14). In fact, in an eye with complete posterior vitreous detachment with severe NPDR, the clinical concern should be more for the possibility of the development of rubeosis iridis, NV of the iris, than of PDR. In some instances, small buds or “popcorn kernels” of NV may appear in eyes with vitreous separation, but such lesions rarely progress or lead to complication. Some investigators have suggested that iatrogenic induction of posterior vitreous detachment in eyes with NPDR, or drug treatment to prevent vitreous senescence and detachment, would be beneficial, since it would prevent the development and complications of PDR (15).
Proliferation and Regression of New Vessels
Initially, new vessels may be very subtle on clinical examination. Their caliber may eventually range up to that of a major retinal vein at the disc margin (Fig. 3). New vessels frequently form wheel-like networks (see Fig. 2). NV networks also may be irregular in
Fig. 3. New vessels elsewhere without prominent network formation. Over much of their course, these new vessels did not form networks. Large aneurysmal dilations were present at the end of a long new vessel loop (left arrow) and at the circumference of a partial wheel-like network (right arrow). (Courtesy Diabetic Retinopathy Study Research Group.)
